Biblio Discovery — Demo Discovery Service

21 results for "Alfred L. Garfall"

Showing 1–20 · 2.42 seconds · RSS

  1. Journal Article

    Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review

    Marco Ruella; Guido Ghilardi; Zainul S. Hasanali et al.

    Journal for ImmunoTherapy of Cancer, Vol. 13 No. 1 · 2025 · English · DOAJ Scopus

    Chimeric antigen receptor T cell (CAR-T) therapies are now standard-of-care for several B-cell malignancies, and additional indications are being evaluated. In this review, we survey data on how outcomes after CAR-T therapies vary according to age, race, and ethnicity. We also review the…

  2. Journal Article

    4473 Immune control of plasma cell disorders – in-depth analysis of Sox2 immunity in MGUS

    Sandra Patricia Susanibar Adaniya; Casey L. Cummins; Miren L. Baroja et al.

    Journal of Clinical and Translational Science, Vol. 4 · 2020 · English · DOAJ Scopus

    OBJECTIVES/GOALS: We aim to identify and characterize anti-Sox2-specific CD8+ T cell responses in stable MUGS patients expressing HLA class I alleles-A*02:01 and /or -B*07:02. METHODS/STUDY POPULATION: Cross sectional study of patients with stable MGUS defined as stable serum paraprotein for ≥ 12…

  3. Journal Article

    A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma

    Alfred L. Garfall; Rahul Banerjee; Laurent Frenzel et al.

    Frontiers in Oncology, Vol. 15 · 2025 · English · DOAJ Scopus

    IntroductionBispecific antibodies (BsAbs) are novel immunotherapy agents for the treatment of relapsed/refractory multiple myeloma (RRMM). Currently, 3 BsAbs (teclistamab, talquetamab, and elranatamab) are approved for the treatment of RRMM. Administering BsAbs in different practice settings is…

  4. Journal Article

    Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

    Amrita Krishnan; Ajay K Nooka; Ajai Chari et al.

    Journal of Comparative Effectiveness Research, Vol. 12 No. 6 · 2023 · English · DOAJ Scopus

    Aim: We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted…

  5. Journal Article

    Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice

    Zainul S. Hasanali; Alfred L. Garfall; Lisa Burzenski et al.

    JCI Insight, Vol. 9 No. 10 · 2024 · English · DOAJ Scopus

    Multiple myeloma is a largely incurable and life-threatening malignancy of antibody-secreting plasma cells. An effective and widely available animal model that recapitulates human myeloma and related plasma cell disorders is lacking. We show that busulfan-conditioned human IL-6–transgenic…

  6. Journal Article

    Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel

    Guido Ghilardi; Luca Paruzzo; Vrutti Patel et al.

    Journal of Hematology & Oncology, Vol. 17 No. 1 · 2024 · English · DOAJ Scopus

    Abstract Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CART products idecabtagene vicleucel and…

  7. Journal Article Full text

    Teclistamab in Relapsed or Refractory Multiple Myeloma

    Philippe Moreau; Alfred L. Garfall; Niels W.C.J. van de Donk et al.

    New England Journal of Medicine · 2022 · English · OpenAlex Scopus

    BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients…

  8. Journal Article

    Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma

    Luca Paruzzo; Khashayar Eshaghi; Guido Ghilardi et al.

    Blood Immunology & Cellular Therapy, Vol. 1 No. 2 · 2025 · English · DOAJ

    Abstract: Chimeric antigen receptor T-cell (CART) therapy targeting B-cell maturation antigen (CART-BCMA) is a transformative treatment for multiple myeloma (MM). However, its high cost and the need for specialized centers may limit access for racial and ethnic minority populations (REMPs), who are…

  9. Journal Article

    Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment

    Danai Dima; Aimaz Afrough; Utkarsh Goel et al.

    Blood Advances, Vol. 9 No. 14 · 2025 · English · DOAJ Scopus

    Abstract: Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was…

  10. Journal Article

    Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

    Danai Dima; Mariola A. Vazquez-Martinez; James A. Davis et al.

    Blood Cancer Journal, Vol. 15 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Data describing outcomes of teclistamab in multiple myeloma patients with prior exposure to BCMA-directed therapy (BCMA-DT) are limited. The goal of this multicenter retrospective analysis was to report the efficacy and safety of standard-of-care teclistamab in patients with prior BCMA-DT…

  11. Journal Article

    The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

    Aimaz Afrough; Danai Dima; Beatrice Razzo et al.

    Blood Cancer Journal, Vol. 16 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers…